On this page
DSG2
desmoglein 2
DSG2 encodes desmoglein 2, a structural protein essential for maintaining cell-to-cell adhesion in heart muscle and other tissues. The DSG2 gene provides instructions for making desmoglein 2, a protein found in desmosomes - specialised junctions that hold adjacent cells together.
DSG2 is located on the long (q) arm of chromosome 18, at band 18q12.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 18 in the library →Overview
DSG2 encodes desmoglein 2, a transmembrane glycoprotein that serves as a critical component of desmosomes throughout the body. Desmosomes are intercellular adhesive structures that anchor adjacent cells together, providing mechanical strength to tissues subjected to physical stress. The protein is particularly abundant in cardiac muscle, where it forms part of specialised junctions called intercalated discs that connect individual heart muscle cells.
Desmoglein 2 belongs to the cadherin superfamily of calcium-dependent adhesion molecules. It spans the cell membrane and interacts with desmoglein 2 molecules on neighbouring cells, creating a strong adhesive bond. Within the cell, desmoglein 2 connects to the intermediate filament cytoskeleton through interactions with intracellular plaque proteins, effectively linking the structural framework of one cell to that of its neighbours.
Pathogenic variants in DSG2 are associated with arrhythmogenic right ventricular cardiomyopathy, an inherited heart condition characterised by progressive replacement of cardiac muscle with fatty and fibrous tissue. This gene is included in the American College of Medical Genetics and Genomics Secondary Findings recommendations, reflecting its clinical importance. The condition follows an autosomal dominant inheritance pattern, meaning a pathogenic variant in one copy of the gene can be sufficient to cause disease.
What the gene does
Desmoglein 2 functions as a core adhesive component of desmosomes, specialised cell junctions that provide mechanical coupling between adjacent cells. The protein achieves this through homophilic interactions, where desmoglein 2 molecules on one cell bind directly to desmoglein 2 molecules on neighbouring cells in the extracellular space. These interactions are calcium-dependent, requiring the presence of calcium ions to maintain the structural integrity of the adhesive bond.
The extracellular portion of desmoglein 2 contains four cadherin repeat domains that mediate cell-to-cell adhesion. These domains adopt a characteristic rod-like structure, with calcium ions bound at the interfaces between adjacent repeats. This calcium binding rigidifies the extracellular segment, allowing it to resist mechanical forces that would otherwise pull cells apart. The extracellular architecture enables desmoglein 2 to withstand the substantial tensile stress experienced by cardiac tissue during each heartbeat.
Within the cell, the cytoplasmic tail of desmoglein 2 interacts with plaque proteins including plakoglobin and plakophilin. These plaque proteins serve as adaptors that connect desmoglein 2 to the intermediate filament network, specifically desmin filaments in cardiac muscle. This molecular bridge transfers mechanical load from the cell surface to the cytoskeleton, distributing stress across the entire cellular architecture. The desmosomal plaque also contains desmoplakin, which directly binds intermediate filaments and completes the structural linkage.
Beyond its structural role, desmoglein 2 participates in cell signalling pathways that regulate tissue development and homeostasis. The protein can influence Wnt signalling through its interactions with plakoglobin, a component that can translocate to the nucleus and modulate gene expression. Disruption of desmosomal integrity may therefore affect both mechanical stability and cellular behaviour. In cardiac tissue, proper desmosomal function is essential for maintaining the organised architecture of intercalated discs, the specialised junctions where mechanical, electrical, and chemical communication occurs between cardiac myocytes.
Video: Genetics 101
Chromosome location
The DSG2 gene is located on the long arm of chromosome 18 at position 12.1, designated cytogenetically as 18q12.1. This chromosomal region contains a cluster of related desmosomal genes, reflecting the evolutionary relationship among cadherin family members. The gene spans a substantial genomic interval and contains 17 exons that encode the mature mRNA transcript.
The genomic organisation of DSG2 includes multiple regulatory elements that control tissue-specific expression patterns. The gene is expressed most abundantly in cardiac muscle, but also appears in epithelial tissues throughout the body, including the skin, gastrointestinal tract, and respiratory epithelium. Alternative splicing has been documented at this locus, potentially generating protein isoforms with subtle functional differences, though the predominant cardiac isoform is well characterised.
The 18q12.1 region shows relative structural stability, with no common large-scale chromosomal rearrangements reported. However, the gene's size and exon-intron structure create multiple opportunities for pathogenic sequence variants to arise, including missense changes, frameshift mutations, and splice-site alterations.
Protein structure
Desmoglein 2 is synthesised as a 1,118 amino acid protein with a modular domain architecture characteristic of classical cadherins. The mature protein contains an N-terminal signal peptide that directs it to the cell membrane, followed by an extracellular region, a single-pass transmembrane domain, and a cytoplasmic tail.
The extracellular segment comprises four tandem cadherin domains: Cadherin 1 spans amino acids 50-160, Cadherin 2 extends from residues 161-273, Cadherin 3 occupies positions 274-388, and Cadherin 4 covers amino acids 389-503. Each cadherin domain adopts a characteristic immunoglobulin-like fold stabilised by calcium-binding sites at the interdomain interfaces. These repeats create the rigid extracellular rod that mediates adhesive interactions with desmoglein 2 molecules on adjacent cells.
Following the transmembrane helix, the intracellular region contains six desmoglein repeats that distinguish desmogleins from classical cadherins. Desmoglein repeat 1 spans amino acids 881-912, repeat 2 covers residues 913-942, repeat 3 extends from positions 943-968, repeat 4 occupies amino acids 969-992, repeat 5 spans residues 993-1,021, and repeat 6 covers positions 1,022-1,051. These repeats mediate interactions with desmosomal plaque proteins, particularly plakoglobin and plakophilin, which anchor the protein to the intermediate filament cytoskeleton.
The C-terminal region, spanning amino acids 1,068-1,118, is disordered and lacks stable secondary structure. This flexible tail may provide additional binding sites for regulatory proteins or post-translational modifications that modulate desmosomal assembly and turnover. The combination of structured adhesive domains and flexible regulatory regions enables desmoglein 2 to perform both mechanical and signalling functions within the desmosome.
Key variants
Pathogenic variants in DSG2 demonstrate considerable heterogeneity in both type and distribution across the gene. Missense variants affecting the extracellular cadherin domains are frequently observed, often disrupting calcium binding or the protein folding required for homophilic adhesion. These substitutions can impair the ability of desmoglein 2 to form stable intercellular bridges, compromising desmosomal integrity.
Truncating variants, including nonsense mutations and frameshift insertions or deletions, result in premature termination of protein synthesis. Such variants typically lead to either absent protein or unstable fragments that cannot fulfil normal adhesive functions. Splice-site variants affecting exon-intron boundaries may cause aberrant mRNA processing, producing transcripts with deleted or duplicated sequences.
Variant penetrance and expressivity show notable variability in DSG2-related cardiomyopathy. Some individuals carrying pathogenic variants develop severe cardiac manifestations early in life, whilst others remain asymptomatic or present with milder phenotypes later. This incomplete penetrance suggests that genetic modifiers, environmental factors, and lifestyle influences contribute to disease expression. The variant's position within the protein, the specific functional domain affected, and the nature of the amino acid change all influence clinical outcomes.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1027G>T | p.Glu343Ter | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.1211C>G | p.Ser404Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.1319_1320del | p.Val440fs | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.136C>T | p.Arg46Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.137G>A | p.Arg46Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.1385del | p.Asn462fs | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.146G>A | p.Arg49His | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.1826dup | p.Leu610fs | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.1971G>A | p.Trp657Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Arrhythmogenic right ventricular dysplasia 10 |
c.2349C>A | p.Tyr783Ter | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in DSG2 are primarily associated with arrhythmogenic right ventricular cardiomyopathy, an inherited heart muscle disorder characterised by progressive replacement of ventricular myocardium with fibrofatty tissue. This condition typically presents with ventricular arrhythmias, which may manifest as palpitations, syncope, or sudden cardiac events. The right ventricle is preferentially affected in the early stages, though left ventricular involvement often develops as the disease progresses.
The pathophysiology of arrhythmogenic right ventricular cardiomyopathy involves gradual loss of cardiac myocytes and their replacement with adipose and fibrous tissue. Defective desmosomal adhesion leads to mechanical uncoupling of cardiac cells, triggering cell death and inflammation. Over time, this process creates a substrate for electrical instability and arrhythmias. Structural imaging may reveal right ventricular dilatation, wall motion abnormalities, and regions of fibrofatty infiltration. Clinical management typically involves arrhythmia monitoring, medications to reduce arrhythmia burden, and in some cases implantable cardioverter-defibrillators to prevent sudden cardiac death.
Inheritance pattern
Conditions caused by pathogenic DSG2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the UK National Health Service Genomic Medicine Service, DSG2 is listed on multiple NHS Genomic Medicine Service PanelApp panels used for clinical genomic testing. The gene holds green (high evidence) status on the Arrhythmogenic right ventricular cardiomyopathy panel, reflecting robust evidence for its role in this condition. It is also rated green on both the Dilated and arrhythmogenic cardiomyopathy panel and the Paediatric or syndromic cardiomyopathy panel, recognising that DSG2 variants can present across different age groups and with overlapping cardiac phenotypes.
DSG2 is included in the American College of Medical Genetics and Genomics Secondary Findings version 3.2 recommendations, meaning laboratories performing clinical exome or genome sequencing are encouraged to report medically actionable pathogenic variants in this gene, even when these variants are not related to the original indication for testing. This designation reflects the gene's clinical importance and the availability of interventions that may reduce morbidity and mortality in carriers. Individuals identified with pathogenic DSG2 variants through genomic testing are typically referred to cardiology services for clinical evaluation, electrocardiographic monitoring, and cardiac imaging to assess disease status and guide management.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with DSG2-related cardiomyopathy, certain lifestyle considerations may be relevant to cardiac health, though evidence remains evolving and recommendations should be personalised through consultation with a cardiac specialist. Research suggests that high-intensity competitive athletics and endurance sports may accelerate disease progression in some individuals with arrhythmogenic right ventricular cardiomyopathy, as sustained vigorous exercise increases mechanical stress on already vulnerable cardiac tissue. Clinical guidelines from cardiology societies, including those adopted by UK cardiology services, often recommend activity restriction for diagnosed individuals, whilst the appropriate level of permissible exercise varies based on disease severity and individual risk stratification.
General cardiovascular health measures that benefit the broader population - such as maintaining healthy body weight, following a balanced diet, avoiding tobacco, and limiting alcohol consumption - remain relevant for individuals with DSG2 variants. These measures support overall cardiac function and may help manage comorbid cardiovascular risk factors. However, no specific dietary pattern has been demonstrated to prevent or reverse arrhythmogenic cardiomyopathy in DSG2 variant carriers.
Stress management and adequate sleep may support general well-being, though direct evidence linking these factors to DSG2-related disease outcomes is limited. Some clinicians advise individuals with known arrhythmogenic cardiomyopathy to avoid stimulants that may provoke arrhythmias, though this guidance should be individualised. Regular follow-up with cardiology services allows for monitoring of disease progression and timely adjustment of management strategies based on clinical status.
Supplement considerations
Currently, no dietary supplements have been shown to prevent or treat arrhythmogenic right ventricular cardiomyopathy caused by DSG2 variants. The disease arises from structural defects in intercellular adhesion, and no micronutrient or botanical supplement has been demonstrated to restore desmosomal function or halt fibrofatty replacement of cardiac tissue.
Some individuals with heart conditions take omega-3 fatty acid supplements based on general cardiovascular health research, but there is no specific evidence that these compounds modify outcomes in DSG2-related cardiomyopathy. Similarly, coenzyme Q10 and other supplements marketed for heart health have not been studied in the context of desmosomal cardiomyopathies. Antioxidant vitamins have been investigated in various cardiac conditions, but no conclusive evidence supports their use for preventing disease progression in individuals with pathogenic DSG2 variants.
Anyone considering dietary supplements should discuss this with their healthcare provider, particularly individuals already taking cardiac medications, as some supplements may interact with prescribed treatments. Clinical management of DSG2-related cardiomyopathy relies on evidence-based interventions including medication, device therapy when indicated, and lifestyle modifications rather than supplementation. Research into targeted therapies for desmosomal cardiomyopathies is ongoing, but at present, standard cardiac care remains the foundation of treatment.
Frequently asked questions
What is the function of the DSG2 gene?
The DSG2 gene provides instructions for making desmoglein 2, a protein that helps hold adjacent cells together, particularly in heart muscle. It forms part of structures called desmosomes that provide mechanical strength to tissues subjected to physical stress.
What conditions are associated with DSG2 variants?
Pathogenic variants in DSG2 are primarily associated with arrhythmogenic right ventricular cardiomyopathy, an inherited heart condition where cardiac muscle is progressively replaced with fatty and fibrous tissue. This can lead to arrhythmias and heart function problems.
How is DSG2-related cardiomyopathy inherited?
DSG2-related cardiomyopathy follows an autosomal dominant inheritance pattern. This means a pathogenic variant in one copy of the gene can be sufficient to cause disease, and an affected individual has a 50% chance of passing the variant to each child.
Why is DSG2 included in secondary findings recommendations?
DSG2 is included in the ACMG Secondary Findings list because pathogenic variants can cause a serious but medically actionable condition. Early identification allows for cardiac monitoring, lifestyle modifications, and potentially life-saving interventions such as implantable defibrillators.
What is the role of desmoglein 2 in the heart?
In cardiac muscle, desmoglein 2 is a key component of intercalated discs - specialised junctions between heart muscle cells. It helps maintain structural integrity during the mechanical stress of repeated contraction, preventing cells from being pulled apart during each heartbeat.
Can lifestyle changes prevent DSG2-related cardiomyopathy?
Lifestyle modifications cannot prevent the condition in individuals carrying pathogenic variants, as it arises from structural protein defects. However, certain adjustments - such as avoiding high-intensity competitive athletics - may be recommended by cardiologists to potentially slow disease progression, though guidance should be individualised based on clinical assessment.